Cost-effectiveness Analysis of Pertuzumab With Trastuzumab in Patients With Metastatic Breast Cancer.
Sign Up to like & getrecommendations! Published in 2022 at "JAMA oncology"
DOI: 10.1001/jamaoncol.2021.8049
Abstract: Importance The initial assessment of pertuzumab use for treatment of metastatic breast cancer by health technology assessment agencies suggested that pertuzumab was not cost-effective. In Ontario, Canada, pertuzumab became funded in November 2013 based on… read more here.
Keywords: cost; cost effectiveness; pertuzumab; trastuzumab ... See more keywords
Efficacy of HD201 vs Referent Trastuzumab in Patients With ERBB2-Positive Breast Cancer Treated in the Neoadjuvant Setting: A Multicenter Phase 3 Randomized Clinical Trial.
Sign Up to like & getrecommendations! Published in 2022 at "JAMA oncology"
DOI: 10.1001/jamaoncol.2021.8171
Abstract: Importance The drug HD201 is a biosimilar candidate for breast cancer treatment as the reference trastuzumab. Objective To compare the efficacy of HD201 with referent trastuzumab. Design, Setting, and Participants This randomized clinical trial (TROIKA)… read more here.
Keywords: breast cancer; trastuzumab; hd201 referent; referent trastuzumab ... See more keywords
Efficacy of Ipilimumab vs FOLFOX in Combination With Nivolumab and Trastuzumab in Patients With Previously Untreated ERBB2-Positive Esophagogastric Adenocarcinoma: The AIO INTEGA Randomized Clinical Trial.
Sign Up to like & getrecommendations! Published in 2022 at "JAMA oncology"
DOI: 10.1001/jamaoncol.2022.2228
Abstract: Importance In metastatic esophagogastric adenocarcinoma (EGA), the addition of programmed cell death 1 (PD-1) inhibitors to chemotherapy has improved outcomes in selected patient populations. Objective To investigate the efficacy of trastuzumab and PD-1 inhibitors with… read more here.
Keywords: oncology; arm; erbb2 positive; trial ... See more keywords
Mammaglobin 1 mediates progression of trastuzumab‐resistant breast cancer cells through regulation of cyclins and NF‐κB
Sign Up to like & getrecommendations! Published in 2022 at "FEBS Open Bio"
DOI: 10.1002/2211-5463.13468
Abstract: Overexpression of human epidermal growth factor receptor 2 (HER2) in various cancers is correlated with poor patient survival. Trastuzumab, a recombinant humanized monoclonal antibody against HER2, has been considered to be a first‐line therapy for… read more here.
Keywords: breast cancer; cancer cells; trastuzumab; regulation ... See more keywords
The effect of trastuzumab on cardiac function in patients with HER2-positive metastatic breast cancer and reduced baseline left ventricular ejection fraction.
Sign Up to like & getrecommendations! Published in 2022 at "International journal of cancer"
DOI: 10.1002/ijc.34024
Abstract: We investigated the effect of trastuzumab on cardiac function in a real-world historic cohort of patients with HER2-positive metastatic breast cancer (MBC) with reduced baseline left ventricular ejection fraction (LVEF). Thirty-seven patients with HER2-positive MBC… read more here.
Keywords: severe cardiotoxicity; patients her2; cancer; her2 positive ... See more keywords
A novel circular RNA confers trastuzumab resistance in human epidermal growth factor receptor 2-positive breast cancer through regulating ferroptosis.
Sign Up to like & getrecommendations! Published in 2022 at "Environmental toxicology"
DOI: 10.1002/tox.23509
Abstract: HER2-positive breast cancer is an aggressive subtype of breast cancer, characterized by high malignancy and poor prognosis. Trastuzumab, the first HER2-targeted monoclonal antibody therapy, has a crucial role in a curative setting in HER2-positive breast… read more here.
Keywords: breast; trastuzumab; ferroptosis; breast cancer ... See more keywords
Pertuzumab, trastuzumab and taxane-based treatment for visceral organ metastatic, trastuzumab-naïve breast cancer: real-life practice outcomes
Sign Up to like & getrecommendations! Published in 2018 at "Cancer Chemotherapy and Pharmacology"
DOI: 10.1007/s00280-018-3712-7
Abstract: PurposeIn this study, we aimed to describe the real-life practice outcomes of pertuzumab–trastuzumab–taxane (PTT) combination in visceral organ metastatic, trastuzumab-naive breast cancer (BC) patients.MethodsThis study was conducted by Turkish Oncology Group and included 317 patients’… read more here.
Keywords: pertuzumab trastuzumab; trastuzumab taxane; metastatic trastuzumab; taxane ... See more keywords
Combination efficacy of pertuzumab and trastuzumab for trastuzumab emtansine-resistant cells exhibiting attenuated lysosomal trafficking or efflux pumps upregulation
Sign Up to like & getrecommendations! Published in 2020 at "Cancer Chemotherapy and Pharmacology"
DOI: 10.1007/s00280-020-04138-5
Abstract: Trastuzumab emtansine (T-DM1) is the standard treatment in the current second-line therapy of human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer. However, a useful therapy after T-DM1 resistance has not been established. In… read more here.
Keywords: combination; resistant cells; dm1; trastuzumab emtansine ... See more keywords
Trastuzumab and survival of patients with metastatic breast cancer
Sign Up to like & getrecommendations! Published in 2017 at "Archives of Gynecology and Obstetrics"
DOI: 10.1007/s00404-017-4421-x
Abstract: IntroductionPrognosis of Her2-positive breast cancer has changed since the introduction of trastuzumab for treatment in metastatic and early breast cancer. It was described to be even better compared to prognosis of Her2-negative metastatic breast cancer.… read more here.
Keywords: her2 positive; trastuzumab; breast cancer; metastatic breast ... See more keywords
Personalized therapeutic strategies in HER2-driven gastric cancer
Sign Up to like & getrecommendations! Published in 2021 at "Gastric Cancer"
DOI: 10.1007/s10120-021-01165-w
Abstract: Trastuzumab is the only approved targeted therapy in patients with HER2-amplified metastatic gastric cancer (GC). Regrettably, in clinical practice, only a fraction of them achieves long-term benefit from trastuzumab-based upfront strategy. To advance precision oncology,… read more here.
Keywords: her2 driven; gastric cancer; trastuzumab; strategies her2 ... See more keywords
Optimal duration of adjuvant trastuzumab in treatment of early breast cancer: a meta-analysis of randomized controlled trials
Sign Up to like & getrecommendations! Published in 2018 at "Breast Cancer Research and Treatment"
DOI: 10.1007/s10549-018-4967-8
Abstract: BackgroundOne year of adjuvant trastuzumab, chosen empirically, improves survival of women with early-stage, Human Epidermal Growth Factor Receptor 2 (HER2) positive breast cancer. Two years of trastuzumab does not improve efficacy but increases cost, inconvenience,… read more here.
Keywords: year; treatment; breast cancer; trastuzumab ... See more keywords